|
Summary
February 2008, Vol. 9, No. 3, Pages 351-362
, DOI 10.1517/14656566.9.3.351
Pharmacotherapy of insomniaAbid Bhat1University of Missouri at Kansas City, Division of Pulmonary and Critical Care Medicine, Geriatrics and Hospital Medicine, Department of Medicine, Truman Medical Center, Hospital Hill, Kansas City, Missouri, USA 2University of Missouri at Kansas City, Division of General Internal Medicine, Geriatrics and Hospital Medicine, Department of Medicine, Truman Medical Center, Hospital Hill, Kansas City, Missouri, USA 3State University of New York at Buffalo, Division of Pulmonary, Critical Care, and Sleep Medicine, Department of Medicine, Erie County Medical Center, 462 Grider Street, Buffalo, New York 14215, USA +1 716 898 3375; +1 716 898 6139; solh@buffalo.edu Insomnia is the most common sleep disorder in the industrialized world. A variety of precipitating events have been identified, but when it becomes a persistent problem, maladaptive patterns become established, thereby, perpetuating the sleep disturbance. Individuals with insomnia have impaired next-day functioning, which impacts their quality of life and places them at increased risk of motor vehicle accidents. Insomnia is commonly associated with chronic medical conditions, as well as an increased incidence of mental disorders. Despite considerable scientific advances in both the understanding and treatment, insomnia continues to be inadequately identified and treated, with < 15% of those with severe insomnia receiving appropriate treatment. The mainstay of treatment for insomnia is cognitive-behavioral therapy, along with judicious use of hypnotic agents. Forward Links to Citing ArticlesMarshall E. Cates, Cherry W. Jackson, Jacqueline M. Feldman, Amanda E. Stimmel, Thomas W. Woolley. (2009) Metabolic Consequences of Using Low-Dose Quetiapine for Insomnia in Psychiatric Patients. Community Mental Health Journal Online publication date: 27-Jun-2009. CrossRef Users who read this article also read:
|
|





Author for correspondence
TOC Alert